See your heart failure patients between visits.
A physician-directed program that brings together your patients' records, an in-office LVEDP test, home lung impedance readings, and each patient's own report of how they feel, so that you have organized information between visits. BridgeCare LA delivers the program in Louisiana as the exclusive licensee of SYNC-PREVENT™, developed by Synchronize Health, LLC.
You stay in charge at every step
You order, interpret, diagnose, and decide. The SYNC-PREVENT platform organizes and displays information, and care team coordinators carry out the workflow you approve. Neither gives medical advice or makes a clinical judgment.
What the program gives your practice
Heart failure care happens at the visit, but a patient's condition changes between visits. The program gives you organized, regular information on your patients between appointments, and a team that does the work of collecting it.
- A review of your whole patient population, including records from your patients' other treating physicians, organized against criteria you approve.
- The Vivio LVEDP test, performed in your office during a regular visit.
- CardioSet lung impedance readings, taken by the patient at home, with every reading reviewed by a person, around the clock.
- Daily home weight and blood pressure readings, as you order, reviewed the same way.
- The KCCQ-12, so you see how the patient feels alongside the test results.
- A specialized care team: a Pharmacy Technician, a Registered Dietitian Nutritionist, and a Certified Diabetes Care and Education Specialist for patients with diabetes, working with each patient every month under your care plan.
of 2,040 adults tested at three primary care clinics had an elevated LVEDP (above 18 mm Hg) on Vivio testing.
Cantu-Martinez et al., JACC Advances 2025 [2]
lower risk of heart failure hospitalization with lung impedance-guided care (20 vs. 95 events; hazard ratio 0.26).
IMPEDANCE-HFpEF, J Card Fail 2026 [5]
The CMS heart failure model's functional status measure lists the KCCQ as a validated instrument.
ACC Practical Guide, 2026 [3]
First performance year of the CMS Ambulatory Specialty Model for heart failure.
ACC Practical Guide, 2026 [3]
Each study describes its own patients and setting. Results from a published study do not predict results for patients in this program, and BridgeCare LA makes no claim that its results will match those published.
Why this matters now
Elevated filling pressure can be present before a patient has heart failure symptoms. The 2026 Second Universal Definition of Heart Failure includes evidence of increased filling pressure, measured by invasive or noninvasive means, within Stage B (pre-heart failure). It also notes that natriuretic peptide levels can be normal in HFpEF despite elevated filling pressure [1].
For general cardiologists in the regions CMS has selected, the CMS Ambulatory Specialty Model begins its first performance year on January 1, 2027. Its heart failure quality measures include risk-standardized acute unplanned cardiovascular-related admission rates for patients with heart failure (MIPS #492) and functional status assessment for heart failure (MIPS #377). Payment adjustments of up to plus or minus 9% apply to Medicare Part B payments two years after the performance year, and the range rises in later years [3].
The program gives you organized information on the patients these measures concern, and it offers the KCCQ-12 after every Vivio test.
Step one: knowing your population
Before the first patient is enrolled, the care team reviews your practice's whole patient population, together with records from each patient's other treating physicians, against criteria you approve. You receive an organized list of the patients who meet those criteria, including information that may not appear in your own record, and you decide which patients to consider for a Vivio test.
The criteria are yours. They can draw on the risk factors the 2022 AHA/ACC/HFSA Heart Failure Guideline describes for Stages A and B, such as high blood pressure, diabetes, chronic kidney disease, obesity, and earlier results such as natriuretic peptide levels or heart imaging, as well as a heart failure diagnosis or a past heart failure hospitalization [4]. Records are exchanged securely under a business associate agreement.
After every Vivio test, whatever the result, the patient is offered the KCCQ-12, a short questionnaire on how heart failure affects daily life. CardioSet monitoring follows only when you judge a Vivio result positive.
The program, step by step
Records and results move between the patient's treating physicians by Direct Secure Messaging and are placed in one program record that you and the care team can see (SYNC Shared Record™).
Lead Coordinator
You order panels such as NT-proBNP, hs-troponin, cystatin-C, ApoB, HbA1c, and FIB-4 for a documented clinical reason, with retesting at set intervals and at any time you choose.
You order
Performed in your office during the patient's visit, by your staff, at your order. The result goes to you and to the care team by Direct Secure Message the same day. You decide whether a result is positive.
Your practice
You order CardioSet monitoring based on the Vivio result. The patient is taught at the diagnostic testing visit and takes the reading at home in a set one-hour slot. You set the parameters and the frequency; the program plans for one reading per month.
You order; the care team teaches and reviews
Offered after every Vivio test, after a heart failure hospitalization, and after a CardioSet reading you judge positive. The system totals the score, an Alert Coordinator reviews it, and you receive the result with the prior score.
Care team
How every home reading is handled
Every reading is reviewed by a person. Alert Coordinators compare each reading with the parameters you have ordered, around the clock. The platform does not decide whether a reading is within range.
Within your ordered range: the Alert Coordinator marks the reading, and the patient receives a text.
Outside your ordered range: the patient receives your approved questions by text. If there is no reply within 15 minutes, the Alert Coordinator calls, asks the same questions, and sends you the notification before the call ends.
Missing reading: the patient is reminded and called if no reading arrives. A caregiver or secondary contact is called if needed, and you are told the same day.
Emergencies: staff follow your practice's own signed 911 policy.
Your daily report: by 10:00 a.m. each business day, your practice administrator receives a list of notices not yet acknowledged, by physician and chart number only, over a secure channel.
Your patients' specialized care team
The 2022 AHA/ACC/HFSA guideline recommends that patients with symptomatic heart failure receive care from a multidisciplinary team, to support guideline-directed medical therapy and self-care [4]. Three specialized clinicians work with each enrolled patient every month under your care plan. Each documents every contact and brings anything that needs a clinical decision to you. None of them changes a medicine, a diet order, or a care plan without your order.
Pharmacy Technician
Holds every medication conversation with the patient. Builds one medication list from every prescriber, including over-the-counter products and supplements; brings to you any medicine known to worsen heart failure, such as NSAIDs; and tracks refills and missed doses of heart failure medicines.
Registered Dietitian Nutritionist
Works with every patient on the sodium limit and any fluid limit you set, including reading food labels and finding the sodium in processed and restaurant foods, and keeps one food plan for patients who also have diabetes or kidney disease.
Certified Diabetes Care and Education Specialist
Works with every patient who has diabetes, so diabetes care and heart failure care follow one plan, including teaching your instructions for SGLT2 inhibitors you prescribe and the self-care that helps patients recognize worsening symptoms.
More services for patients with heart failure
These services use the same workflow and are carried out only as you order. Each follows the 2022 AHA/ACC/HFSA guideline [4].
Care after a hospital discharge: medication reconciliation against the discharge medicines, a contact with the patient soon after discharge, and help scheduling the follow-up visit you order.
Heart failure medicine summary: each patient's heart failure medicines grouped by guideline drug class. Two of the CMS heart failure model's quality measures concern these medicines: ACE inhibitor, ARB, or ARNI therapy (MIPS #5) and beta-blocker therapy (MIPS #8) for left ventricular systolic dysfunction [3].
Iron studies: ferritin and transferrin saturation available as lab options for patients with heart failure.
Lab checks after medicine changes: when you order potassium and kidney function tests after starting or raising a medicine, we confirm the test is drawn and the result reaches the record.
Vaccination status: gaps in respiratory vaccinations found in the shared record are brought to you.
Cardiac rehabilitation: when you refer a patient, we help them arrange attendance and record it.
Sleep assessment: sleep-disordered breathing was found in 76% of 700 patients with symptomatic heart failure and reduced ejection fraction, and in 69.3% of 244 patients with heart failure and normal ejection fraction [6, 7]. Among 1,117 patients hospitalized with acute heart failure, both obstructive and central sleep apnea were associated with higher mortality over a median of 3 years after discharge [8]. The program brings any earlier sleep study into the record and helps schedule the formal sleep assessment you order.
What sets the program apart
It starts with your whole population. You begin with an organized list built from your patients' records and their other physicians' records, against your criteria.
You see the whole record, not just your own chart. Records from each patient's treating physicians come together in one program record, kept in a federally certified electronic health record and exchanged by Direct Secure Messaging.
Measured results and the patient's own report, side by side. The Vivio test, monthly CardioSet readings, and the KCCQ-12 are recorded together, so you can consider them as a whole.
A person reviews every reading, around the clock. Missing readings are followed up the same day.
Your clinical authority is built in. You approve the criteria, order every test, judge every result, and set every parameter. Your emergency and notification policies are loaded before any patient is added.
Our team carries the workload. A Lead Coordinator and an Assistant Lead Coordinator are assigned to your practice, supported by testing coordinators, Alert Coordinators, a Patient Engagement and Care Coordinator, and the specialized care team.
Heart failure care within whole-patient care. Enrolled patients take part in the full SYNC-PREVENT program for their other chronic conditions, as you order.
The published evidence
The program applies the principles used in the studies below. Each study describes its own patients and setting. Results from a published study do not predict results for patients in this program, and BridgeCare LA makes no claim that its results will match those published.
| Study | Design and population | Reported results |
|---|---|---|
| Cantu-Martinez et al., JACC Advances 2025 [2] | Cross-sectional convenience sample of 2,040 adults tested at 3 primary care clinics (diabetes, chronic kidney disease, or suspected heart failure); mean age 74. | 38.5% had an elevated LVEDP (above 18 mm Hg) on Vivio testing. Of 653 KCCQ-OS scores collected, 31.4% scored 100 (asymptomatic) and 26.5% scored below 80, consistent with NYHA class II–IV. |
| IMPEDANCE-HFpEF, J Card Fail 2026 [5] | Randomized, single-blind, single-center trial of 150 patients with HFpEF (LVEF above 50%, elevated NT-proBNP, and a prior heart failure hospitalization); follow-up 38.4 months. | Impedance-guided care was associated with fewer heart failure hospitalizations: 20 vs. 95 events (hazard ratio 0.26, a 74% lower risk). All-cause death (hazard ratio 0.40, a 60% lower risk) and heart failure death (hazard ratio 0.26, a 74% lower risk) were also lower. |
About the devices. Each device's cleared use belongs to that device and its manufacturer, and is described in the manufacturer's labeling. SYNC-PREVENT does not assert or inherit a device's claims. The Vivio System (510(k) K223905) is a test for elevated left ventricular end-diastolic pressure. The CardioSet Edema Guard Monitor (510(k) K250922) is a lung impedance monitor; a reading is an adjunct to standard clinical assessment and is not the sole input used to guide treatment.
What your practice does and what we do
| Your practice | BridgeCare LA care team |
|---|---|
| Approves the population review criteria | Reviews your population and delivers the organized list |
| Refers each patient with a care plan and the patient's consent | Assigns a Lead Coordinator and an Assistant Lead Coordinator to your practice |
| Orders tests and reviews results | Provides diagnostic testing coordinators; teaches home devices at the testing visit |
| Performs the Vivio test during visits; the device stays at your practice | Reviews every home reading around the clock and notifies you |
| Interprets results, diagnoses, and decides therapy | Offers and reviews the KCCQ-12 and sends you the results |
| Writes the care plan the specialized care team follows | Provides a Pharmacy Technician, a Registered Dietitian Nutritionist, and a CDCES for patients with diabetes |
| Handles insurance verification and preapproval | Sends your practice administrator a daily report of open notices |
Getting started
- 01
Agreement. Your practice and BridgeCare LA sign the program agreement and a business associate agreement.
- 02
Your practice's policies. You complete the onboarding questionnaire: your 911 policy, contacts and office hours, who receives notices, and who performs the Vivio test and records results. These are loaded as your practice's fixed policy before any patient is added.
- 03
Criteria and population review. You approve the criteria, and we deliver the organized list of patients who meet them.
- 04
Your team is assigned. Your Lead Coordinator and Assistant Lead Coordinator are introduced, and diagnostic testing is scheduled. Your practice obtains insurance preapproval for patients aged 50 to 64 and for patients aged 65 and older on Medicare Advantage plans.
- 05
First patients. You refer patients with a care plan and their consent, perform the Vivio test at their visit, and order monitoring as you judge appropriate.
Bring the program to your practice
A complimentary 30-minute conversation with our team, for physician practices only, with no obligation.
Schedule a ConsultationReferences
- AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). JACC (Just Accepted).
- Cantu-Martinez O, Girard AA, Jin W, et al. Noninvasive screening for elevated LVEDP and health status in outpatients at risk for heart failure. JACC Advances. 2025;4(8):102002. doi:10.1016/j.jacadv.2025.102002
- American College of Cardiology. Navigating the Ambulatory Specialty Model for HF: A Practical Guide. Fall 2026.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032.
- Kleiner-Shochat M, et al. Lung Impedance Guided Therapy Reduces Hospitalizations in Heart Failure with Preserved Ejection Fraction: A Randomized Trial (IMPEDANCE-HFpEF). J Card Fail. 2026. doi:10.1016/j.cardfail.2026.07.019
- Oldenburg O, Lamp B, Faber L, Teschler H, Horstkotte D, Töpfer V. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail. 2007;9(3):251–257.
- Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail. 2009;11(6):602–608.
- Khayat R, Jarjoura D, Porter K, et al. Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. Eur Heart J. 2015;36(23):1463–1469.
BridgeCare LA, the exclusive Louisiana licensee of SYNC-PREVENT™, operates monitoring programs under physician direction. The platform collects and transmits device data, but does not interpret it or make treatment recommendations. Clinical decisions rest solely with the treating physician.